BOB体育

Skip to main content
(352) 294-5757

Barry J Byrne, MD, PhD

Pediatric Cardiologist

Photo of Barry J Byrne
(352) 294-5757 MyUFHealth

Research at a glance

Top areas of exploration

  • Genetic Therapy , 88 publications
  • Genetic Vectors , 80 publications
  • Glycogen Storage Disease Type II , 61 publications
  • Muscle, Skeletal , 42 publications

Research activity

361 publications

22,175 citations

Why is this important?

Active clinical trials

Pfizer Early Stage GT

The study will evaluate the safety and dystrophin expression following gene therapy in boys with Duchenne Muscular Dystrophy (DMD). It is a single-arm, non-randomized, open-label study

Investigator
Barry J Byrne
Status
Accepting Candidates
Ages
2 Years - 3 Years
Sexes
Male
ATB200-08

This is a Phase 3, open-label, multicenter study to evaluate the safety, efficacy, PK, PD, and immunogenicity of cipaglucosidase alfa/miglustat treatment in ERT-experienced and ERT-na茂ve pediatric subjects with IOPD.

Investigator
Barry J Byrne
Status
Accepting Candidates
Ages
N/A - 17 Years
Sexes
All
TECPR2 Obs

The purpose of this study is to learn more about the disease progression in patients with a TECPR2 mutation.

Investigator
Barry J Byrne
Status
Accepting Candidates
Ages
18 Months - 12 Years
Sexes
All

My publications

361 publications

2024

Innate Immune Sensing of Adeno-Associated Virus Vectors.

Human gene therapy

鈥�

2024

Kenneth I. Berns, MD, PhD [1938-2024].

Human gene therapy

鈥�

2024

Long-term safety and efficacy of cipaglucosidase alfa plus miglustat in individuals living with Pompe disease: an open-label phase I/II study (ATB200-02)

Journal of Neurology

鈥�

2024

Longitudinal changes of swallowing safety and efficiency in infants with spinal muscular atrophy who received disease modifying therapies

Pediatric Pulmonology

2024

Meeting Report: 2023 Muscular Dystrophy Association Summit on 'Safety and Challenges in Gene Therapy of Neuromuscular Diseases'.

Journal of neuromuscular diseases

鈥�